179 related articles for article (PubMed ID: 30481559)
1. Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome.
Tang J; Srinivasan S; Yuan W; Ming R; Liu Y; Dai Z; Noble CO; Hayes ME; Zheng N; Jiang W; Szoka FC; Schwendeman A
Eur J Pharm Biopharm; 2019 Jan; 134():107-116. PubMed ID: 30481559
[TBL] [Abstract][Full Text] [Related]
2. Analytical method development and comparability study for AmBisome® and generic Amphotericin B liposomal products.
Liu Y; Mei Z; Mei L; Tang J; Yuan W; Srinivasan S; Ackermann R; Schwendeman AS
Eur J Pharm Biopharm; 2020 Dec; 157():241-249. PubMed ID: 32980448
[TBL] [Abstract][Full Text] [Related]
3. Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes.
Yuan W; Kuai R; Dai Z; Yuan Y; Zheng N; Jiang W; Noble C; Hayes M; Szoka FC; Schwendeman A
AAPS J; 2017 Jan; 19(1):150-160. PubMed ID: 27485642
[TBL] [Abstract][Full Text] [Related]
4. Critical process parameters in manufacturing of liposomal formulations of amphotericin B.
Rivnay B; Wakim J; Avery K; Petrochenko P; Myung JH; Kozak D; Yoon S; Landrau N; Nivorozhkin A
Int J Pharm; 2019 Jun; 565():447-457. PubMed ID: 31071418
[TBL] [Abstract][Full Text] [Related]
5. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience.
Adler-Moore J; Proffitt RT
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():21-30. PubMed ID: 11801577
[TBL] [Abstract][Full Text] [Related]
6. Temperature-dependent transfer of amphotericin B from liposomal membrane of AmBisome to fungal cell membrane.
Shimizu K; Osada M; Takemoto K; Yamamoto Y; Asai T; Oku N
J Control Release; 2010 Jan; 141(2):208-15. PubMed ID: 19815038
[TBL] [Abstract][Full Text] [Related]
7. Development of liposomal amphotericin B formulation.
Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
[TBL] [Abstract][Full Text] [Related]
8. In vitro in vivo relations for the parenteral liposomal formulation of Amphotericin B: A biorelevant and clinically relevant approach.
Díaz de León-Ortega R; D'Arcy DM; Lamprou DA; Xue WF; Fotaki N
Eur J Pharm Biopharm; 2021 Feb; 159():188-197. PubMed ID: 32717384
[TBL] [Abstract][Full Text] [Related]
9. Comparison between liposomal formulations of amphotericin B.
Adler-Moore JP; Gangneux JP; Pappas PG
Med Mycol; 2016 Mar; 54(3):223-31. PubMed ID: 26768369
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of size-based distribution of drug and excipient in amphotericin B liposomal formulation.
Van Haute D; Jiang W; Mudalige T
Int J Pharm; 2019 Oct; 569():118603. PubMed ID: 31401296
[TBL] [Abstract][Full Text] [Related]
11. Fungal fatal attraction: a mechanistic review on targeting liposomal amphotericin B (AmBisome
Soo Hoo L
J Liposome Res; 2017 Sep; 27(3):180-185. PubMed ID: 28805117
[TBL] [Abstract][Full Text] [Related]
12. The care and feeding of a commercial liposomal product: liposomal amphotericin B (AmBisome
Jensen GM
J Liposome Res; 2017 Sep; 27(3):173-179. PubMed ID: 28967274
[TBL] [Abstract][Full Text] [Related]
13. Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability.
Morand K; Bartoletti AC; Bochot A; Barratt G; Brandely ML; Chast F
Int J Pharm; 2007 Nov; 344(1-2):150-3. PubMed ID: 17669608
[TBL] [Abstract][Full Text] [Related]
14. Liposomal formulations of amphotericin B: differences according to the scientific evidence.
Azanza JR; Sádada B; Reis J
Rev Esp Quimioter; 2015 Dec; 28(6):275-81. PubMed ID: 26621170
[TBL] [Abstract][Full Text] [Related]
15. USP Apparatus 4: a Valuable In Vitro Tool to Enable Formulation Development of Long-Acting Parenteral (LAP) Nanosuspension Formulations of Poorly Water-Soluble Compounds.
Forrest WP; Reuter KG; Shah V; Kazakevich I; Heslinga M; Dudhat S; Patel S; Neri C; Mao Y
AAPS PharmSciTech; 2018 Jan; 19(1):413-424. PubMed ID: 28755052
[TBL] [Abstract][Full Text] [Related]
16. Differences in human phospholipid transfer protein activity following incubation of Fungizone compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma.
Henderson RJ; Leon CG; Wasan KM
Drug Dev Ind Pharm; 2009 Sep; 35(9):1139-46. PubMed ID: 19381990
[TBL] [Abstract][Full Text] [Related]
17. Novel biodegradable poly(gamma-glutamic acid)-amphotericin B complexes show promise as improved amphotericin B formulations.
Dinh T; Zia Q; Zubair S; Stapleton P; Singh R; Owais M; Somavarapu S
Nanomedicine; 2017 Jul; 13(5):1773-1783. PubMed ID: 28216150
[TBL] [Abstract][Full Text] [Related]
18. Liposomal and lipid-based formulations of amphotericin B.
de Marie S
Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cells.
Sperry PJ; Cua DJ; Wetzel SA; Adler-Moore JP
Med Mycol; 1998 Jun; 36(3):135-41. PubMed ID: 9776826
[TBL] [Abstract][Full Text] [Related]
20. Accelerated in vitro release testing method for naltrexone loaded PLGA microspheres.
Andhariya JV; Choi S; Wang Y; Zou Y; Burgess DJ; Shen J
Int J Pharm; 2017 Mar; 520(1-2):79-85. PubMed ID: 28153651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
